Dec 30, 2025 • MarketBeat
SOMEWHAT-BEARISH
Voya Investment Management LLC Trims Stock Holdings in Sarepta Therapeutics, Inc. $SRPT
Voya Investment Management LLC significantly reduced its stake in Sarepta Therapeutics, Inc. ($SRPT) by 99.5% in the third quarter of 2025. This move leaves Voya Investment Management LLC with a minimal holding, while other institutional investors like UBS, Assenagon, and Aberdeen Group increased their positions, collectively owning 86.68% of the company. Despite an EPS miss and a consensus "Hold" rating from analysts with an average price target of $33.68, other institutions are increasing their stakes in the biotechnology company.
Dec 29, 2025 • openPR.com
BULLISH
Japan Gene Therapy Market is expected to reach US$ 904.94 Million by 2033 | Major Companies - Alnylam Pharmaceuticals, Inc., NOVARTIS AG, Sarepta Therapeutics, Inc., Krystal Biotech, Inc.
The Japan Gene Therapy Market was valued at US$ 148.06 Million in 2024 and is projected to grow to US$ 904.94 Million by 2033, exhibiting a CAGR of 20.3%. This growth is fueled by increasing R&D, regulatory support, and advancements in personalized medicine. Key players in this market include Alnylam Pharmaceuticals, Inc., Novartis AG, Sarepta Therapeutics, Inc., and Krystal Biotech, Inc.
Dec 28, 2025 • CBS 17
BEARISH
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. (SRPT) after the company announced its late-stage ESSENCE trial for two gene therapies failed to meet statistical significance on its primary endpoint. This news led to a significant drop in Sarepta's stock price. The law firm is encouraging stockholders to contact them for more information regarding this securities investigation.
Dec 27, 2025 • FOX 2
BEARISH
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sarepta Therapeutics, Inc. (SRPT) after the company announced on November 3, 2025, that its ESSENCE trial for two gene therapies did not meet its primary endpoint, causing a significant drop in its stock price. The firm is encouraging investors who purchased Sarepta securities to learn more about the investigation and potentially participate. This legal action aims to recover investor capital and ensure corporate accountability.
Dec 26, 2025 • KSNT 27 News
BEARISH
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sarepta Therapeutics, Inc. (SRPT) following a significant drop in its stock price. This decline occurred after Sarepta announced on November 3, 2025, that its late-stage ESSENCE trial for two Duchenne muscular dystrophy gene therapies, AMONDYS 45 and VYONDYS 5, did not meet its primary endpoint, causing a 33.74% share price fall. The firm is encouraging investors who purchased Sarepta securities to join the investigation.
Dec 26, 2025 • Fox 59
BEARISH
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating Sarepta Therapeutics, Inc. (SRPT) after the company disclosed that its ESSENCE trial for two Duchenne muscular dystrophy gene therapies did not meet its primary endpoint, causing a significant stock price drop. The firm encourages investors who purchased Sarepta securities to join the investigation. This aims to recover investor capital and ensure corporate accountability.